# Evotec SE > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Evotec SE). ## Overview Evotec SE is a life science company that provides drug discovery and development services across small molecules, biologics, cell therapies, and related modalities. It operates through a network of scientific platforms and partnerships with pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders in Europe and the United States. ## Products & services • Drug discovery and preclinical development services • Integrated R&D programs and long-term partnering models • Biologics design and manufacturing through Just - Evotec Biologics • iPSC-based disease modelling and PanOmics platforms • Molecular Patient Databases and data-driven discovery tools • Co-owned proprietary R&D assets in therapeutic programs - **Discovery & Development Services** (60%) — Standalone and integrated services for drug discovery, preclinical research, and development. - **Biologics Development & Manufacturing** (20%) — Just - Evotec Biologics capabilities for biologics design, process development, and manufacturing. - **Strategic Partnerships** (10%) — Long-term collaboration models with pharma, biotech, and research institutions. - **Proprietary R&D Assets** (10%) — Co-owned and partnered therapeutic programs and related intellectual property. - Drug discovery and preclinical development services - Integrated R&D programs and long-term partnering models - Biologics design and manufacturing through Just - Evotec Biologics - iPSC-based disease modelling and PanOmics platforms - Molecular Patient Databases and data-driven discovery tools - Co-owned proprietary R&D assets in therapeutic programs ## Customers Evotec sells primarily to pharmaceutical companies, biotechnology firms, academic institutions, and other healthcare stakeholders that outsource research and development work or seek strategic collaboration. Its customer base uses Evotec for scientific capabilities, specialized platforms, and flexible partnership models that can range from discrete projects to multi-year programs. The business is designed to support customers across the drug development pipeline, from early discovery to biologics process development. - **Global pharmaceutical companies** (primary) — Buy discovery, preclinical, and biologics development services to augment internal R&D pipelines. - **Biotechnology companies** (primary) — Use Evotec for specialized scientific platforms, development capacity, and partnership structures. - **Academic and research institutions** (secondary) — Engage Evotec for platform access, translational research support, and collaborative programs. - **Other healthcare stakeholders** (secondary) — Use the company for outsourced drug discovery, disease modelling, and integrated R&D support. - Top pharmaceutical companies outsourcing discovery and development work - Biotechnology companies needing specialized R&D capabilities - Academic and research institutions using platform-based services - Healthcare stakeholders seeking biologics and translational expertise - Partners that want integrated programs instead of single projects ## Geography Evotec operates from sites in Europe and the United States, with scientific and operational work distributed across a global network of centres of excellence. The company’s footprint matters because discovery, development, and biologics capabilities are delivered close to major pharmaceutical and biotechnology clusters while also supporting cross-border partnering. - Operations span Europe and the United States - Scientific sites support distributed research and development delivery - Geography matters for proximity to pharma and biotech customers - Global network enables collaboration across time zones and disciplines - United States and Europe are the core commercial and operating regions ## Strategy Evotec’s strategy centers on combining scientific platforms with AI-enabled discovery, advanced technologies, and flexible partnering structures. It also emphasizes biologics development and manufacturing through Just - Evotec Biologics, while maintaining a portfolio of proprietary and co-owned research assets that can create optionality over time. - **Scale integrated drug discovery and development partnerships** (medium-term) — Deeper partnerships improve customer stickiness and broaden project scope across the value chain. - **Grow biologics design and manufacturing capabilities** (medium-term) — Biologics capabilities widen the addressable market and add higher-complexity service offerings. - **Leverage proprietary scientific platforms and data assets** (long-term) — Platforms such as PanOmics and iPSC models strengthen differentiation and improve discovery productivity. - Use AI-driven and data-enabled discovery platforms to improve output - Expand integrated partnering models with pharma and biotech clients - Develop Just - Evotec Biologics as a differentiated biologics platform - Advance proprietary and co-owned R&D assets across therapeutic areas - Focus on oncology, cardiovascular, metabolic, neurology, and immunology ## Risks Evotec faces execution risk from complex, project-based drug discovery work, where revenue depends on winning and delivering scientific programs for external partners. The business is also exposed to funding and spending cycles in biotech, while its multinational footprint adds currency, credit, and operational complexity. - **Revenue timing and project execution risk** [high] — The company depends on successful delivery of research programs and customer acceptance across multiple project stages. - **Biotech customer funding volatility** [high] — Many customers are biotechnology companies whose spending can slow when financing conditions tighten. - **Foreign exchange risk** [medium] — Operations and customers span Europe and the United States, creating exposure to multiple currencies. - **Asset impairment risk** [high] — Specialized laboratory and property assets may need write-downs if capacity is underused or plans change. - **Credit and liquidity risk** [medium] — The company extends services to a wide set of counterparties and must fund working capital across programs. - Project and milestone timing can shift revenue recognition - Biotech customer funding cycles affect demand for services - Complex scientific programs carry delivery and execution risk - Currency and liquidity risks arise from international operations - Asset impairment and restructuring provisions can affect results ## Accounting A major accounting focus for Evotec is revenue recognition across service contracts, integrated programs, and partnering arrangements, where timing depends on project progress and deliverables. Investors should also watch fair value measurements, impairments, and provisions, because the company carries scientific assets, laboratory facilities, investments, and restructuring-related estimates that can materially affect reported results. - **Revenue recognition for research and partnership contracts** — Affects revenue timing and comparability across periods - **Impairment of property and laboratory assets** — Can create significant non-cash charges - **Fair value measurement of investments** — Can add volatility to other income and gains - **Restructuring provisions** — Affects operating expenses and liabilities - Revenue recognition depends on project milestones and contract delivery - Integrated partnerships can involve variable consideration and estimates - Impairment testing matters for laboratory buildings and long-lived assets - Fair value gains and losses affect investment-related results - Restructuring and severance provisions rely on management estimates --- *Last updated: 2026-09-28T12:03:35.330156+00:00*